EGFR and non-small cell lung carcinoma: These findings suggest a multifactorial process through which ARID1A mutations increase tumor proliferation and metastasis, and decrease the sensitivity of ARID1A/EGFR‐comutated NSCLC to EGFR TKI therapy.